B. Riley assumed coverage on shares of Arbutus Biopharma (NASDAQ:ABUS) in a research report sent to investors on Friday morning. The firm issued a buy rating and a $10.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on the company. Chardan Capital reiterated a buy rating on shares of Arbutus Biopharma in a research report on Wednesday, September 13th. ValuEngine downgraded Arbutus Biopharma from a hold rating to a sell rating in a research report on Wednesday, October 25th. BidaskClub downgraded Arbutus Biopharma from a sell rating to a strong sell rating in a research report on Thursday, December 14th. Zacks Investment Research upgraded Arbutus Biopharma from a sell rating to a hold rating in a research report on Tuesday, November 7th. Finally, JMP Securities reiterated an outperform rating and issued a $13.00 price objective (up previously from $12.00) on shares of Arbutus Biopharma in a research report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Arbutus Biopharma currently has an average rating of Hold and a consensus target price of $12.50.

Shares of Arbutus Biopharma (NASDAQ:ABUS) opened at $5.55 on Friday. The stock has a market capitalization of $302.79, a price-to-earnings ratio of -1.12 and a beta of 1.08. Arbutus Biopharma has a 12-month low of $2.35 and a 12-month high of $8.25. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Arbutus Biopharma by 2.7% during the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,035 shares in the last quarter. OxFORD Asset Management LLP raised its position in Arbutus Biopharma by 89.9% during the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 39,436 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Arbutus Biopharma during the second quarter valued at about $478,000. Point72 Asset Management L.P. purchased a new stake in Arbutus Biopharma during the third quarter valued at about $1,393,000. Finally, RTW Investments LP raised its position in Arbutus Biopharma by 1.1% during the third quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after purchasing an additional 56,457 shares in the last quarter. Institutional investors and hedge funds own 59.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Arbutus Biopharma (ABUS) Coverage Initiated by Analysts at B. Riley” was posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/arbutus-biopharma-abus-coverage-initiated-by-analysts-at-b-riley/1797488.html.

About Arbutus Biopharma

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.